Interaction of human fibrinogen receptor (GPIIb-IIIa) with decorsin

Acta Pharmacologica Sinica

Volumn 25, Issue 8, 2004, Pages 1096-1104

  Yang, Jie ^a   Zhan, Chen Yang ^a   Dong, Xian Chi ^a   Yang, Kun ^a   Wang, Fu Xiang ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Decorsin; Drug design; Platelet glycoprotein GPIIb IIIa complex

Indexed keywords

AMINO ACID; ARGININE; ARGINYLGLYCYLASPARTIC ACID; ASPARAGINE; ASPARTIC ACID; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; LYSINE; PROLINE; THREONINE; VITRONECTIN RECEPTOR;

ARTICLE; DRUG BINDING SITE; DRUG RECEPTOR BINDING; HYDROGEN BOND; MOLECULAR INTERACTION; MOLECULAR MODEL; NUCLEOTIDE SEQUENCE; STRUCTURE ANALYSIS;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; DRUG DESIGN; HUMANS; INTEGRIN ALPHA2; INTEGRIN ALPHA5; LEECHES; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROTEINS;

EID: 4043077703     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Senti M, Aubo C, Bosch M, Pavesi M, Pena A, Masia R, et al. Platelet glycoprotein IIb/IIIa genetic polymorphism is associated with plasma fibrinogen levels in myocardial infarction patients. Clin Biochem 1998; 31: 647-51.
2. Schulman SP, Goldschmidt-Clermont PJ, Topol E J, Califf RM, Navetta FI, Willerson JT, et al. Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial. Circulation 1996; 94: 2083-9.
3. Menegatti M, Asselta R, Duga S, Malcovati M, Bucciarelli P, Mannucci PM, et al. Identification of four novel polymorphisms in the Alpha and gamma fibrinogen genes and analysis of association with plasma levels of the protein. Thromb Res 2001; 103: 299-307.
4. Law DA, Nannizzi-Alaimo L, Phillips DR. Outside-in integrin signal transduction. αIIbβ3-(GPIIb/IIIa) tyrosine phosphorylation induced by platelet aggregation. J Biol Chem 1996; 271: 10811-5.
5. Wu H, Peng L, Li J, Wu W, Hou Q, Liu H, et al. Reversible exposure of human platelet fibrinogen receptors by antiplatelet tetraspanin monoclonal antibodies via induction of a conformational change in membrane glycoprotein IIb/IIIa complex. Thromb Res 1999; 95: 245-53.
6. Jenkins AL, Nannizzi-Alaimo L, Silver D, Sellers JR, Ginsberg MH, Law DA, et al. Tyrosine phosphorylation of the β3 cytoplasmic domain mediates integrin-cytoskeletal interactions. J Biol Chem 1998; 273: 13878-85.
7. Law DA, DeGuzman FR, Heiser P, Ministri-Madrid K, Killeen N, Phillips DR. Integrin cytoplasmic tyrosine motif is required for outside-in αIIbβ3 signaling and platelet function. Nature 1999; 401: 808-11.
8. Parise LV. Integrin αIIbβ3 signaling in platelet adhesion and aggregation. Curr Opin Cell Biol 1999; 11: 597-601.
9. Weller T, Alig L, Muller MH, Kouns WC, Steiner B. Fibrinogen receptor antagonists - a novel class of promising antithrombotics. Drugs Future 1994; 19: 461-76.
10. Seymour JL, Henzel WJ, Nevins B, Stults JT, Lazarus RA. Decorsin, a potent glycoprotein IIb/IIIa antagonist and platelet aggregation inhibitor from the leech Macrobdella decora. J Biol Chem 1990; 265: 10143-7.
11. Topol EJ, Byzove TV, Plow EF. Platelet GPIIb/IIIa blockers. Lancet 1999; 353: 227-31.
12. Polverino de Laureto P, Scaramella E, De Filippis V, Marin O, Doni MG, Fontana A. Chemical synthesis and structural characterization of the RGD-protein decorsin: a potent inhibitor of platelet aggregation. Protein Sci 1998; 7: 433-44.
13. Xiong JP, Stehle T, Diefenbach B, Zhang R, Dunker R, Scott DL, et al. Crystal Structure of the extracellular segment of integrin alpha V/beta 3. Science 2001; 294: 339-46.
14. Krezel AM, Wagner G, Seymour-Ulmer J, Lazarus RA. Structure of the RGD protein decorsin: conserved motif and distinct function in leech proteins that affect blood clotting. Science 1994; 264: 1944-7.
15. Johnson MS, Srinivasan N, Sowdhamini R, Blundell TL. Knowledge-Based Protein Modeling. Biochem Mol Biol 1994; 29: 1-68.
16. Tang Y, Chen KX, Jiang HL, Ji RX. Molecular modeling of mu opioid receptor and its interaction with ohmefentanyl. Acta Pharmacol Sin 1996; 17: 156-60.
17. Yang J, Liu CQ. Molecular modeling on human CCR5 receptors and complex with CD4 antigens and HIV-1 envelope glycoprotein gp120. Acta Pharmacol Sin 2000; 21: 29-34.
18. Yang J, Liu CQ. Interaction between human interleukin-16 and CD4 receptor of HIV-I. Acta Pharmacol Sin 2000; 21: 547-53.
19. Yang J, Zhang YW, Huang JF, Zhang YP, Liu CQ. Structure analysis of CCR5 from human and primates. J Mol Struct Theochem 2000; 505: 199-210.
20. Yang J, Liu CQ. Molecular modeling on some human interleukins sharing gamma c of interleukin-2 receptor, and structure-function relationships. J Mol Struct Theochem 2000; 532: 1-10.
21. Basani RB, D'Andrea G, Mitra N, Vilaire G, Richberg M, Kowalska MA, et al. RGD-containing peptides inhibit fibrinogen binding to platelet alpha(IIb)beta3 by inducing an allosteric change in the amino-terminal portion of alpha(IIb). J Biol Chem 2001; 276: 13975-81.
22. Basani RB, French DL, Vilaire G, Brown DL, Chen F, Coller BS, et al. A naturally occurring mutation near the amino terminus of alpha IIb defines a new region involved in ligand binding to alpha IIb beta 3. Blood 2000; 95: 180-8.
23. Stattil SJ. Signaling through platelet integrin alpha IIb beta 3: inside-out, outside-in, and sideways. Thromb Haemost 1999; 82: 318-25.
24. Basanoval AV, Baskoval IP, Zavalova LL. Vascular-Platelet and Plasma Hemostasis Regulators from Bloodsucking Animals. Biochemistry (Mosc) 2002; 67: 143-50.